The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://philipesqy091778.bloggin-ads.com/62119357/glp-3-retatrutide-a-comparative-analysis